A program director at the National Cancer Institute has outlined his vision for how federal IT initiatives can help healthcare adapt to the rise of wearables and ever larger datasets. The process will begin by identifying the core analytic and IT system components all researchers need, regardless of whether they are focused on cancer, diabetes or other diseases.
Top academic centers have contributed structural modeling tools to the push to develop treatments for Ebola. A team at Scripps is behind the first tool, which is designed to show researchers which parts of the Ebola virus to target.
If the U.S. National Institutes of Health gets its way, any researcher it funds will have to publish a summary of their clinical trial results and adverse events, regardless of whether the trial succeeded or failed.
Proponents of DNA printing have heralded it as a way to do everything from bringing alien life back from Mars to delivering vaccines in the event of a pandemic. And the technology has attracted GlaxoSmithKline and Roche, both of which have taken an interest in Cambrian Genomics.
BioNano Genomics has restocked its coffers to fund an assault on the genome analysis sector. The San Diego, CA-based genome mapping firm raised a $53 million war chest from Novartis' venture fund and other investors to accelerate uptake of its Irys DNA analysis device and accompanying software.
GlaxoSmithKline and Medidata have moved mHealth tools one step closer to the clinical trial mainstream. Having run a pilot project, the partners have concluded that mHealth technologies can deliver reliable, FDA-compliant data and improve the clinical trial experience for patients.
Pathway Genomics had a busy week. The San Diego, CA-based genetic testing laboratory began by securing an investment from IBM that will also give it access to Watson, before going on to form a cancer research collaboration with a registry created by researchers from Memorial Sloan Kettering, Mayo Clinic, Dana-Farber and other organizations.
The EMA responded quickly to the publication of the letter, issuing a release to outline its approach to the redaction of commercial confidential information.
Bioinformatics has taken another step toward cementing itself in the life sciences mainstream. The latest validation of the importance of informatics comes from the Association for Molecular Pathology, which has established a subdivision focused on the field.
The U.K. government has set out its vision for how the National Health Service will transform into a tech-savvy, research-enabling organization by 2020. As part of the wide-reaching strategy, NHS England will create "test bed" sites at which bioinformatics approaches and other tools will be tested.
Genomics England has revealed part of how it plans to turn the huge amount of data generated by the 100,000 Genomes Project into insights into rare diseases and cancers. From today, British researchers who want to work with the data can apply to access the resource.
J. Craig Venter's Human Longevity, Inc. has added another piece to the data tapestry it is creating. The new addition is a registry of 11,000 twins, complete with phenotypic information and paired samples.
Thermo Fisher Scientific has confirmed its Kinetica software will generate inaccurate results when analyzing unbalanced clinical trials, Reuters reports.
Google is going after your genome. The search giant has spent the past 18 months building its Google Genomics platform and pitching it to researchers as a way to store human genomes for $25 each per year.
In 2003, a team of scientists and IT engineers set out to create a map of which proteins are found in each part of the body. Now, after committing more than 1,000 man years to the project, the team has released the Human Protein Atlas, an interactive map of the proteome containing 13 million annotated images.
The space occupied by Google Flu Trends is becoming more congested. One year after the Centers for Disease Control and Prevention put out a call for ways to use digital data to forecast the flu season, details of the entrants' models are still trickling in as academic papers are published.
As part of its immuno-oncology strategy, AstraZeneca's biotech unit MedImmune will pay $150 million upfront and commit to undisclosed milestone fees to take over German data analysis firm Definiens.
The FDA resumed its active search for a CIO late last month, more than one year after it first advertised the position, Regulatory Focus reports.
J. Craig Venter has made new hires at two of his companies.
Google has made the biggest change to its Flu Trends influenza tracking software since it first released the system in 2008. The update incorporates data from the Centers for Disease Control and Prevention in an attempt to improve the accuracy of the model.